Inherited retinal diseases (IRDs) such as retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, and Best macular dystrophy are devastating blinding diseases in people. While mutations in nearly 270 genes have been associated with different forms of IRDs to date, characterization of disease mechanisms and identification of therapeutic targets for many of these IRDs are yet to be developed. Encouraging clinical successes with gene replacement therapy have emerged in recent years for several forms of IRD in man, and some of these treatments have resulted from proof of principle studies carried out in dog models by our research group. At the Retinal Disease Study Facility of the University of Pennsylvania, we have an established research capability and expertise that has allowed us to mechanistically assess over 20 canine strains and their crosses, each of which represent different forms of naturally-occurring IRDs. Using a subset of these canine models, we aim to better understand the molecular basis and pathogenic mechanisms of these unique IRDs, and evaluate new therapies to prevent or ameliorate disease. Thus renewal of the proposed program will allow continued advances in translational studies using canine models of IRDs, providing a sound basis for future development of new and effective therapies for human retinal degenerative diseases. At our centralized resource facility, we will breed and maintain specific canine IRD strains with rigorously characterized phenotypes/genotypes. Investigators will be provided with mutant and age-matched control dogs either for independent or collaborative studies.
The aim of these studies is to understand the molecular mechanisms involved in IRDs, and develop new therapies that can be evaluated on a short- or long-term basis. This centralized resource will also be used by multiple investigators to accomplish the research goals of their own NIH-funded grants. Lastly, hypothesis-driven studies by the PIs and collaborators will be aimed at characterizing new patient-relevant IRD models, studying their underlying cellular/molecular mechanisms, examining the role of inflammation and microglia/macrophages in IRDs for the identification of optimal therapeutic targets, optimizing targeting of different retinal cell types such as ON-bipolar cells, and testing the effect of a new protease in facilitating intravitreal AAV therapies. Our principal hypothesis is that the collaborative research using canine models from a centralized, well- maintained resource facility, supported by a team of investigators with expertise in both clinical ophthalmology and molecular/cell biology, will lead to critical proof-of-principle studies directed at developing safe and effective new therapies for IRDs in patients. The proposed program and studies are designed to fully address this hypothesis.

Public Health Relevance

Inherited retinal diseases that lead to devastating blinding conditions were previously considered incurable, but a handful of them can now be treated with emerging new gene therapy options. However, before potential therapies can be made available for patients, it is critical that they are tested for effectiveness and evaluated for safety in appropriate clinically-relevant model systems. The research proposal aims to understand the mechanisms of genetic mutations causing retinal diseases, and to establish preclinical proof-of-principle by developing and testing new therapies that prevent or delay the retinal degeneration that leads to blindness.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Diseases and Pathophysiology of the Visual System Study Section (DPVS)
Program Officer
Shen, Grace L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Veterinary Sciences
Schools of Veterinary Medicine
United States
Zip Code
Guziewicz, Karina E; McTish, Emily; Dufour, Valerie L et al. (2018) Underdeveloped RPE Apical Domain Underlies Lesion Formation in Canine Bestrophinopathies. Adv Exp Med Biol 1074:309-315
Guziewicz, Karina E; Cideciyan, Artur V; Beltran, William A et al. (2018) BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proc Natl Acad Sci U S A 115:E2839-E2848
Cideciyan, Artur V; Sudharsan, Raghavi; Dufour, Valérie L et al. (2018) Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc Natl Acad Sci U S A 115:E8547-E8556
Miyadera, Keiko (2018) Mapping of Canine Models of Inherited Retinal Diseases. Adv Exp Med Biol 1074:257-264
Hardcastle, Alison J; Sieving, Paul A; Sahel, José-Alain et al. (2018) Translational Retinal Research and Therapies. Transl Vis Sci Technol 7:8
Sudharsan, Raghavi; Elliott, Michael H; Dolgova, Natalia et al. (2018) Photoreceptor Outer Segment Isolation from a Single Canine Retina for RPE Phagocytosis Assay. Adv Exp Med Biol 1074:593-601
Das, Rueben G; Marinho, Felipe Pompeo; Iwabe, Simone et al. (2017) Variabilities in retinal function and structure in a canine model of cone-rod dystrophy associated with RPGRIP1 support multigenic etiology. Sci Rep 7:12823
Yeh, Connie Y; Koehl, Kristin L; Harman, Christine D et al. (2017) Assessment of Rod, Cone, and Intrinsically Photosensitive Retinal Ganglion Cell Contributions to the Canine Chromatic Pupillary Response. Invest Ophthalmol Vis Sci 58:65-78
Sudharsan, Raghavi; Beiting, Daniel P; Aguirre, Gustavo D et al. (2017) Involvement of Innate Immune System in Late Stages of Inherited Photoreceptor Degeneration. Sci Rep 7:17897
Ye, Guo-Jie; Komáromy, András M; Zeiss, Caroline et al. (2017) Safety and Efficacy of AAV5 Vectors Expressing Human or Canine CNGB3 in CNGB3-Mutant Dogs. Hum Gene Ther Clin Dev 28:197-207

Showing the most recent 10 out of 203 publications